Tissue Regenix Proposes Acquisition of CellRight Technologies

Tissue Regenix announced its proposed acquisition of CellRight Technologies for US $30MM. Combined, the companies would offer products for bone and soft tissue regeneration based on CellRight's human-derived bone grafts and Tissue Regenix’s dCELL® decellularization platform.

CellRight gains access to a new geographies for its...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us